tetrahydroisoquinoline with sodium borohydride. The synthesis of the headgroup 56 has been completed according to Scheme S4.
Scheme S4. Synthesis of the headgroup
The formation of the dimethylene spacer was accomplished by a Wittig reaction, however, for this reaction, the corresponding phosphine salt had to be prepared. First, chloromethyl-benzyl ether (51) was reacted with triphenylphosphine (Scheme ). The thus-formed phosphonium salt 52 was converted under basic conditions to the corresponding phosphorane that was then reacted with compound 53. After the isolation of the expected derivative 54, the benzyl group was removed, and the double bond of the side chain was saturated in one step by catalytic hydrogenation. The resulting compound 55 was reacted with methanesulfonic acid chloride to form 56 equipped by the appropriate leaving group for the alkylation reaction. Finally, the headgroup was coupled to the linker derivatives using inorganic bases in acetonitrile at 100 °C (Error! Reference source not found.). In the case of pyrrolopyrimidine linkers 45a-d, the different basicity of the amide nitrogen atoms was used to carry out the reaction regioselectively. Here, test reactions were carried out using various inorganic bases (NaHCO3, Na2CO3 and K2CO3). Potassium carbonate was the first base the use of which led to the formation of the desired products 57a−d, while the other isomer was not formed in any case. After the coupling, carboxylic acid esters were hydrolyzed in dioxane−water (1:1) to give the target compounds 16-19. Reactions starting from tetrahydroisoquinolines 48a−d and 50a−c were accomplished in an analogous manner, via esters 58a−g that were finally hydrolized to the target compounds 20-26. Dose response curve obtained for compound 13 using the HRP/Amplex red assay
Results from differential scanning fluorimetry (DSF) measurements

Limit dose (20 μM) screening results obtained for compounds 8-13 and 16-26
Inhibition percentages with standard deviations are plotted in the figure below.
Experimental
General Information
Melting points were determined on an OptiMelt SRS (Sunnyvale, CA, USA) and are uncorrected. NMR measurements were performed on System 500 NMR spectrometer (Varian, Palo Alto, CA, USA) or a Varian System 300 NMR spectrometer, 1 H and 13 C-NMR spectra were measured at room temperature (25 °C) in an appropriate solvent. 1 H and 13 C chemical shifts are expressed in parts per million (δ) referenced to TMS or residual solvent signals. Reactions were monitored with silica gel 60 F254 TLC plates (Merck, Darmstadt, Germany). All chemicals and solvents were used as purchased. HPLC-MS measurements were performed using a LC-MS-2020 device (Shimadzu, Kyoto, Japan) equipped with a Reprospher 100 C18 (5 µm, 100 × 3mm) column and positive-negative double ion source (DUIS) with a quadrupole mass spectrometer in a range of 50-1000 m/z. Sample was eluted with gradient elution using eluent A (0.1% formic acid in water) and eluent B (0.1% formic acid in acetonitrile). Flow rate was set to 1.5 mL/min. The initial condition was 0% B eluent, followed by a linear gradient to 100% B eluent by 2 min, from 2 to 3.75 min 100% B eluent was retained, and from 3.75 to 4.5 min back to initial condition and retained to 5 min. The column temperature was kept at 30 °C and the injection volume was 1 µl. High resolution mass spectrometric measurements were performed using a Q-TOF Premier mass spectrometer (Waters, Milford, MA, USA) in positive electrospray ionization mode.
Chemistry
6-{2-[4-(4-Chlorophenyl)-7-hydroxy-2-oxo-2H-chromen-6-yl]ethyl}-4-hydroxypyridazin-3(2H)-one (9).
To the solution of 6-[2-(2,4-dihydroxyphenyl)ethyl]-4-hydroxypyridazin-3(2H)-one (38, 100 mg, 0.40 mmol) in methanesulfonic acid (5 mL) was added ethyl 3-(4-chlorophenyl)-3-oxopropanoate (31a, 91 mg, 0.40 mmol). The reaction mixture was stirred at RT for 1 h, then it was quenched with distilled water (10 mL), and the precipitate was filtered and washed with isopropyl alcohol (5 mL) and purified by preparative HPLC (water-acetonitrile 10% to 100% acetonitrile) to give compound 9 (9.0 mg, 0.022 mmol, 6% yield). 1 
4-Hydroxy-6-{2-[7-hydroxy-4-(4-methylphenyl)-2-oxo-2H-chromen-6-yl]ethyl}pyridazin-3(2H)-one (10).
To the solution of 6-[2-(2,4-dihydroxyphenyl)ethyl]-4-hydroxypyridazin-3(2H)-one (38, 100 mg, 0.40 mmol) in methanesulfonic acid (5 mL) was added ethyl 3-(4-methylphenyl)-3-oxopropanoate (31b, 82 mg, 0.40 mmol). The reaction mixture was stirred at RT for 1 h, then it was quenched with distilled water (10 mL), and the precipitate was filtered and washed with isopropyl alcohol (5 mL) and purified by preparative HPLC (water-acetonitrile 10% to 100% acetonitrile) to give the title compound 10 (7.0 mg, 0.018 mmol, 5% yield To the solution of 6-methyl-5-nitropyrimidine-2,4(1H,3H)-dione (40, 5.00 g, 29.2 mmol) in DMF (190 mL), Na2CO3 (7.75 g, 73.1 mmol) and benzyl bromide (8.67 mL, 73.0 mmol) were added. The reaction mixture was stirred at RT for 16 h, then water (270 mL) was added. The solution was washed with ethyl acetate (3 × 250 mL). The combined organic phase was dried over MgSO4, filtered and evaporated. The combined organic phase was dried over MgSO4, filtered and evaporated to give 1,3-dibenzyl-6-methyl- To the solution of 1,3-dibenzyl-6-methyl-5-nitropyrimidine-2,4(1H,3H)-dione (41, 10.00 g, 28.5 mmol) in DMF (20 mL), DMF-DMA (7.4 mL, 72.7 mmol) was added and stirred for 2 h at 65 °C. The reaction mixture was cooled to RT, methanol (5 mL) was added, then diethyl ether (100 mL) was added dropwise. 
6-{2-[4-(3-Chlorophenyl)-7-hydroxy-2-oxo-2H-chromen-6-yl]ethyl}-4-hydroxypyridazin-3(2H)-one (11
General procedure for the preparation of 5-substituted 1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives 45a−d.
To the solution of 1,3-dibenzyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione (43) in NMP, CuBr (2.00 eq), Na2CO3 (1.05 eq) and the corresponding aryl bromide (3.30 eq) were added, then the suspension was heated to 170 °C under argon atmosphere for 3 days. The mixture was filtered through celite and washed with THF twice, then purified by reverse phase flash column chromatography. After the isolation of the desired product 44a−d, it was dissolved in THF (30 mL). 300 m/m% Pd on carbon was added and hydrogenated in autoclave under 5 bar H2 pressure for 3 days at 170 °C (the pressure at 170 °C was ca. 22 bar). It was cooled to RT, the suspension was filtered through celite and washed with THF. After removal of the solvent, the expected product was obtained.
Synthesis of 5-phenyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione (45a).
The reaction was carried out according to the general procedure, starting from 450 mg (1. 
Synthesis of 5-(3-methylphenyl)-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione (45b).
The reaction was carried out according to the general procedure, starting from 450 mg (1.36 mmol) 1,3-dibenzyl-1H-pyrrolo [3,2- 
General procedure for the preparation of 8-substituted 3,4-dihydroisoquinoline derivatives 47a-d.
In a microwave tube, to the solution of 8-chloro-3,4-dihydroisoquinoline hydrochloride (46) in a toluene-water mixture (3:1, 4 mL), potassium fluoride (4.00 eq), tetrakis(triphenylphosphine)palladium(0) (0.015 eq), and the corresponding phenylboronic acid (1.2 eq) were added and reacted in a microwave reactor at 120 °C for 4 h. The phases were separated, the organic layer was dried over MgSO4, filtered and evaporated. The crude product was purified by reverse phase flash column chromatography. 
8-Phenyl-3,4-dihydroisoquinoline (47a)
.
8-(3-Methoxyphenyl)-3,4-dihydroisoquinoline (47c)
8-(4-Methylphenyl)-3,4-dihydroisoquinoline (47d)
General procedure for the preparation of 8-substituted 1,2,3,4-tetrahydroisoquinoline derivatives 48a−d, 50a−c.
To the solution of the corresponding 8-substituted 3,4-dihydroisoquinoline in methanol, NaBH4 (1.1 eq) was added at 0 °C, then the mixture was stirred at RT for 1 h. After the reaction was completed, water was added to the mixture, and washed with DCM twice. The organic phase was dried over MgSO4, filtered and evaporated. The product was used in the next step without further purification. Methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (48c) Methyl-8-pyrrolidin-1-yl-1,2,3,4-tetrahydroisoquinoline (50c) . The reaction was carried out according to the general procedure, starting from 2.00 g (9.99 mmol) 8-pyrrolidin-1-yl-3,4-dihydroisoquinoline (49c), 40 mL methanol, 416 mg (11 mmol) NaBH4 to give 4-methyl-8-pyrrolidin-1-yl-1,2,3,4-tetrahydroisoquinoline (50c, 
8-Phenyl-1,2,3,4-tetrahydroisoquinoline (48a)
8-(3-Methylphenyl)-1,2,3,4-tetrahydroisoquinoline (48b
8-(3-
4-Methyl-8-piperidin-1-yl-1,2,3,4-tetrahydroisoquinoline (50a)
4-
4-[(E)-2-(benzyloxy)ethenyl]-1H-pyrrole-2-carboxylate
(54). The suspension of [(benzyloxy)methyl](triphenyl)phosphonium chloride (52, 9.00 g, 21.5 mmol) in dry THF (100 mL) was stirred and cooled to −78 °C, then butyllithium solution was added dropwise (7.75 mL, 19.4 mmol), and stirred at −78 °C for 30 min. To this solution, ethyl 4-formyl-1H-pyrrole-2-carboxylate (53, 0.90 g, 5.38 mmol) dissolved in dry THF (10 mL) was added dropwise and the reaction was warmed to RT and stirred for 16 h. The organic layer was washed with water, dried over MgSO4 The solution of the corresponding esters (57a−d, 58a−g) in dioxane-1 M NaOH (1:1, 4 mL) was stirred for 2 h, then set to pH 7 with 1 M HCl solution and the solvent was removed. The resulting crude product was suspended with ethanol (2 mL) and filtered. After the evaporation of the solvent, the expected product was obtained. [3,2-d] 
Ethyl 4-{2-[(methylsulfonyl)oxy]ethyl}-1H-pyrrole-2-carboxylate (56)
Ethyl 4-{2-[8-(3-methylphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}-1H-pyrrole-2-carboxylate (58b)
4-[2-(2,4-Dioxo-5-phenyl-1,2,4,5-tetrahydro-3H-pyrrolo[3,2-d]pyrimidin-3-yl)ethyl]-1H-pyrrole-2-carboxylic acid
4-{2-[5-(3-Methylphenyl)-2,4-dioxo-1,2,4,5-tetrahydro-3H-pyrrolo
